search
Back to results

Reducing Self-stigma in Persons With HIV and Drug Use Disorders in Primary Health Care Settings

Primary Purpose

Drug Use Disorders, HIV/AIDS

Status
Completed
Phase
Not Applicable
Locations
Puerto Rico
Study Type
Interventional
Intervention
CBT-based intervention
Treatment as Usual
Sponsored by
University of Puerto Rico
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Drug Use Disorders focused on measuring Self-stigma, Drug Use Disorders, HIV

Eligibility Criteria

21 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Spanish speakers that comply with

  • A drug use disorder based on the Spanish version of the short form of the WHO Composite International Diagnostic Interview (CIDI) that has been used widely in Puerto Rico;
  • HIV clinical criteria;
  • Moderate to higher levels of HIV felt self-stigma (>25);
  • Using the clinic as the main source of medical care during the study; and
  • Agreement to random assignment

Exclusion Criteria:

  • DUD/HIV+ individuals who are not prescribed ART;
  • An acute medical emergency (physical or psychiatric),
  • Unable to provide informed consent
  • Who are actively suicidal.
  • Cognitive impairment or dementia based on a score of 24 or less on the Mini Mental State Examination

Sites / Locations

  • University of Puerto Rico Medical Sciences Campus

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Experimental

Arm Label

Control

Intervention

Arm Description

Treatment as usual

CBT-based intervention

Outcomes

Primary Outcome Measures

Substance Abuse Self-stigma Scale (change is being assessed)
Psychometrically sound and culturally adapted, this is a 40-item scale that contains four sub-scales that measures self-devaluation, fear of enacted stigma, stigma avoidance, and values disengagement due to self stigma. Internal consistency coefficients for the sub-scales ranged from .82 to .88. Study participants will need to endorse at least three items from the self-devaluation sub-scale to be considered as presenting self-stigma (this will be used as an inclusion criteria). Item endorsement will be analyzed as a count, per sub-scale. The greater number of items endorsed per sub-scale, will be indicative of a higher level of self-stigma as manifested by the sub-scale construct.

Secondary Outcome Measures

HIV Felt-stigma Scale (change is being assessed)
The scale measures felt and enacted stigma constructs among persons living with HIV (PLWHIV). Developed for Spanish-speaking populations, this is a 17-item, self-administered multi-dimensional measure for felt and enacted stigma in PLWHIV, using a 4-point Likert scale and that is culturally-sensitive. Exhibits adequate alpha and Pearson correlation coefficients (0.91 and 0.68, respectively) and convergent validity. The scale has four dimensions which scores will be summed to obtain a total scale score. The total scale score is indicative of the level of HIV-related felt stigma experienced by a person. Scale ranges are interpreted as follows: 0-15 no stigma; 16-24 mild; 25-35 moderate; and > 35 severe. For this study, a total score of > 25 is required for enrollment.
Depressive symptoms (change is being assessed)
To assess depressive symptoms, the study will use The Patient Health Questionnaire, depression module: Is a 8 item validated measure. The Spanish version showed a sensitivity of 77% and a specificity of 100% when compared to the Structured Clinical Interview for DSM mood module. The higher the score obtained on the scale, the greater the manifestation of depressive symptoms.
Adherence to Combination Therapy Questionnaire (change is being assessed)
The research team have completed translation, back-translation, and agreements with an expert/bilingual panel of the Single-Item Self-Rating Adherence Scale (SRSI). This is a single item scale that has been use successfully among the health sector.

Full Information

First Posted
September 14, 2018
Last Updated
October 1, 2019
Sponsor
University of Puerto Rico
search

1. Study Identification

Unique Protocol Identification Number
NCT03684252
Brief Title
Reducing Self-stigma in Persons With HIV and Drug Use Disorders in Primary Health Care Settings
Official Title
Reducing Self-stigma in Persons With HIV and Drug Use Disorders in Primary Health Care Settings
Study Type
Interventional

2. Study Status

Record Verification Date
October 2019
Overall Recruitment Status
Completed
Study Start Date
April 9, 2019 (Actual)
Primary Completion Date
June 25, 2019 (Actual)
Study Completion Date
August 31, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Puerto Rico

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The investigators propose to lay the groundwork for a larger effectiveness clinical trial that will lead to the advancement of a novel evidence-based treatment for DUD and HIV among Spanish-speaking Latinos who suffer from self-stigma and have inadequate treatment adherence. This pilot project aims to: compare the outcomes of a culturally adapted CBT-based intervention to treatment as usual (TAU), in a randomized pilot trial of HIV+ individuals with a lifetime DUD.
Detailed Description
This treatment model, new for Puerto Rico, should improve compliance with ART and health outcomes for Latino patients who have largely been excluded from efficacy and effectiveness studies, and thus have not benefited from these advances. The proposed research lays the groundwork to provide the benefits of theoretically grounded, culturally adapted, and evidence-based treatment to reduce self-stigma and increase drug and HIV treatment adherence among Puerto Ricans that may also apply to other Spanish-speaking patients. The investigators work is guided by the Stage Model for Behavior Therapy that recognizes that the scientific study of behavior therapies involves a systematic developmental process that progresses from feasibility (Stage I) to efficacy (Stage II) to effectiveness (Stage III). The proposed research focuses on Stage Ib where the investigators propose to conduct a pilot randomized control trial to compare the outcomes between a novel CBT-based intervention and treatment as usual (TAU) among HIV/DUD+ Latinos reporting self-stigma who are receiving care in a primary care health setting. Assessments of self-stigma and HIV and drug treatment adherence for all participants will be collected pre-treatment and post-treatment. This model allows to lay the groundwork for a larger effectiveness clinical trial. The investigators plan to enroll 16 patients who will be randomly assigned to the CBT (n=8) or to TAU (n=8). Sample size considers a 35% attrition rate as based in previous research experiences among similar population. Patients will be recruited in primary health care clinics in PR. Participants will be randomly assigned to (a) treatment as usual or (b) a Cognitive and Behavioral Therapy. This intervention is a theoretically-based efficacious treatment for self-stigma and related depression. It consists of weekly 60-minute sessions for 6-8 weeks; is flexible and can be modified to fit the needs of individual clients. The intervention is designed to help individuals to employ acceptance and values-directed behavior change strategies in order to increase psychological flexibility, a process that is at the core of behavioral health and retention in treatment. Overall, analyses will allow generating an effect size that can be used to calculate the number of subjects needed for adequate power to detect significant differences between groups.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Drug Use Disorders, HIV/AIDS
Keywords
Self-stigma, Drug Use Disorders, HIV

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
17 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
Other
Arm Description
Treatment as usual
Arm Title
Intervention
Arm Type
Experimental
Arm Description
CBT-based intervention
Intervention Type
Behavioral
Intervention Name(s)
CBT-based intervention
Intervention Description
Cognitive Behavioral Therapy (CBT) that uses acceptance and mindfulness strategies, together with commitment and behavior change strategies.
Intervention Type
Other
Intervention Name(s)
Treatment as Usual
Intervention Description
Participants' will receive treatment as usual.
Primary Outcome Measure Information:
Title
Substance Abuse Self-stigma Scale (change is being assessed)
Description
Psychometrically sound and culturally adapted, this is a 40-item scale that contains four sub-scales that measures self-devaluation, fear of enacted stigma, stigma avoidance, and values disengagement due to self stigma. Internal consistency coefficients for the sub-scales ranged from .82 to .88. Study participants will need to endorse at least three items from the self-devaluation sub-scale to be considered as presenting self-stigma (this will be used as an inclusion criteria). Item endorsement will be analyzed as a count, per sub-scale. The greater number of items endorsed per sub-scale, will be indicative of a higher level of self-stigma as manifested by the sub-scale construct.
Time Frame
Change from baseline/pre-treatment at any point from last intervention (for both groups) to up to 2 weeks after
Secondary Outcome Measure Information:
Title
HIV Felt-stigma Scale (change is being assessed)
Description
The scale measures felt and enacted stigma constructs among persons living with HIV (PLWHIV). Developed for Spanish-speaking populations, this is a 17-item, self-administered multi-dimensional measure for felt and enacted stigma in PLWHIV, using a 4-point Likert scale and that is culturally-sensitive. Exhibits adequate alpha and Pearson correlation coefficients (0.91 and 0.68, respectively) and convergent validity. The scale has four dimensions which scores will be summed to obtain a total scale score. The total scale score is indicative of the level of HIV-related felt stigma experienced by a person. Scale ranges are interpreted as follows: 0-15 no stigma; 16-24 mild; 25-35 moderate; and > 35 severe. For this study, a total score of > 25 is required for enrollment.
Time Frame
Change from baseline/pre-treatment at any point from last intervention (for both groups) to up to 2 weeks after
Title
Depressive symptoms (change is being assessed)
Description
To assess depressive symptoms, the study will use The Patient Health Questionnaire, depression module: Is a 8 item validated measure. The Spanish version showed a sensitivity of 77% and a specificity of 100% when compared to the Structured Clinical Interview for DSM mood module. The higher the score obtained on the scale, the greater the manifestation of depressive symptoms.
Time Frame
Change from baseline/pre-treatment at any point from last intervention (for both groups) to up to 2 weeks after
Title
Adherence to Combination Therapy Questionnaire (change is being assessed)
Description
The research team have completed translation, back-translation, and agreements with an expert/bilingual panel of the Single-Item Self-Rating Adherence Scale (SRSI). This is a single item scale that has been use successfully among the health sector.
Time Frame
Change from baseline/pre-treatment at any point from last intervention (for both groups) to up to 2 weeks after

10. Eligibility

Sex
All
Minimum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Spanish speakers that comply with A drug use disorder based on the Spanish version of the short form of the WHO Composite International Diagnostic Interview (CIDI) that has been used widely in Puerto Rico; HIV clinical criteria; Moderate to higher levels of HIV felt self-stigma (>25); Using the clinic as the main source of medical care during the study; and Agreement to random assignment Exclusion Criteria: DUD/HIV+ individuals who are not prescribed ART; An acute medical emergency (physical or psychiatric), Unable to provide informed consent Who are actively suicidal. Cognitive impairment or dementia based on a score of 24 or less on the Mini Mental State Examination
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Coralee Perez-Pedrogo, PhD
Organizational Affiliation
University of Puerto Rico
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Puerto Rico Medical Sciences Campus
City
San Juan
ZIP/Postal Code
00936
Country
Puerto Rico

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Reducing Self-stigma in Persons With HIV and Drug Use Disorders in Primary Health Care Settings

We'll reach out to this number within 24 hrs